menu
    • menu
    [{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alkermes Plc \/ Clovis Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Alkermes Plc \/ Clovis Oncology"},{"orgOrder":0,"company":"CyGenica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CyGenica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CyGenica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CyGenica \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MBT5","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ERS Genomics","sponsor":"IRBM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ERS Genomics \/ IRBM","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomics \/ IRBM"},{"orgOrder":0,"company":"ERS Genomics","sponsor":"Lepton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ERS Genomics \/ Lepton Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomics \/ Lepton Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JZP815","moa":"Fibrosarcoma","graph1":"Oncology","graph2":"Preclinical","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JZP815","moa":"Fibrosarcoma","graph1":"Oncology","graph2":"Preclinical","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"NY-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Naya Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"ONK Therapeutics \/ Naya Biosciences"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    Ă—
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CyGenica

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            CyGenica

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CyGenica Limited Secures USFDA Approval for Orphan Drug Designation for Novel Drug Conjugate in Glioblastoma M...

                            Details : Nucleotide-based Therapy drug conjugate is the first application of their targeted intracellular delivery platform, GEENIE, for glioblastoma multiforme treatment.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ONK Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            ONK Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONKT105,NY-303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimall...

                            Details : The partnership aims to explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody for the treatment of cancer.

                            Product Name : ONKT105

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : ONKT105,NY-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ONK Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            ONK Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONKT102

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Develo...

                            Details : ONKT102 is the company’s most advanced program, and is being advanced towards clinical development as a potential treatment for patients with relapsed or refractory multiple myeloma (MM).

                            Product Name : ONKT102

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 29, 2022

                            Lead Product(s) : ONKT102

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jazz Pharmaceuticals

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            Jazz Pharmaceuticals

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JZP815

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Proper...

                            Details : JZP815 did not induce significant paradoxical pathway activation, observed with approved first generation BRAF-selective inhibitor, demonstrated equivalent cellular potencies for MAPK pathway inhibition driven by either mutant RAF monomers in tumor cells...

                            Product Name : JZP815

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : JZP815

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jazz Pharmaceuticals

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            Jazz Pharmaceuticals

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JZP815

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Researc...

                            Details : JZP815 is an investigational, pre-clinical stage, next-generation pan-RAF kinase inhibitor, demonstrated that it selectively and potently inhibits mutant A, B and CRAF kinases, and demonstrated anti-tumor activity in RAS- and RAF-mutant xenograft models.

                            Product Name : JZP815

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 03, 2022

                            Lead Product(s) : JZP815

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ERS Genomics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            ERS Genomics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lepton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

                            Details : miRNAs are noncoding RNAs that each affects the expression of hundreds of coding genes. The Castling technology utilizes miRNA pairs that impact immune-cells activity when in the microenvironment of cancer cells.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lepton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ONK Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            ONK Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONKT102

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

                            Details : ONKT102 combines an optimized affinity CD38 CAR and a TRAILv targeting DR5, intended for the treatment of patients with relapsed/refractory multiple myeloma.

                            Product Name : ONKT102

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 09, 2021

                            Lead Product(s) : ONKT102

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nabriva Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBT5,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

                            Details : This new discovery offers the potential to develop novel therapeutics for difficult-to-treat cancers, based on peptides encoded in the mitochondrial genome.

                            Product Name : MBT5

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 01, 2020

                            Lead Product(s) : MBT5,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alkermes Plc

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            Alkermes Plc

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemvaleukin Alpha,Lucitanib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Clovis Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 AACR Virtual Annual Me...

                            Details : The study evaluated the antitumor efficacy and mechanism of action of mALKS 4230, a mouse ortholog of ALKS 4230, and lucitanib as monotherapies and in combination in a preclinical syngeneic mouse model of colon cancer.

                            Product Name : ALKS 4230

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 22, 2020

                            Lead Product(s) : Nemvaleukin Alpha,Lucitanib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Clovis Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Shorla Oncology

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            Shorla Oncology

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SH-105

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Seroba Life Sciences

                            Deal Size : $8.3 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Shorla Nabs $8.3M to Bring Improved Cancer Meds to the U.S.

                            Details : The funding will support the advancement of the product pipeline, along with expansion of technical and commercial operations in both Ireland and the US.

                            Product Name : SH-105

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 06, 2020

                            Lead Product(s) : SH-105

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Seroba Life Sciences

                            Deal Size : $8.3 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth